Emavusertib
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Emavusertib
- DrugBank Accession Number
- DB18060
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 491.508
Monoisotopic: 491.191716933 - Chemical Formula
- C24H25N7O5
- Synonyms
- 4-oxazolecarboxamide, n-(5-((3r)-3-hydroxy-1-pyrrolidinyl)-2-(4-morpholinyl)oxazolo(4,5-b)pyridin-6-yl)-2-(2-methyl-4-pyridinyl)-
- External IDs
- AU-4948
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- MH5DMF9JKY
- CAS number
- 1801344-14-8
- InChI Key
- SJHNWSAWWOAWJH-MRXNPFEDSA-N
- InChI
- InChI=1S/C24H25N7O5/c1-14-10-15(2-4-25-14)23-27-18(13-35-23)22(33)26-17-11-19-20(28-21(17)31-5-3-16(32)12-31)29-24(36-19)30-6-8-34-9-7-30/h2,4,10-11,13,16,32H,3,5-9,12H2,1H3,(H,26,33)/t16-/m1/s1
- IUPAC Name
- N-{5-[(3R)-3-hydroxypyrrolidin-1-yl]-2-(morpholin-4-yl)-[1,3]oxazolo[4,5-b]pyridin-6-yl}-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide
- SMILES
- CC1=CC(=CC=N1)C1=NC(=CO1)C(=O)NC1=C(N=C2N=C(OC2=C1)N1CCOCC1)N1CC[C@@H](O)C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 84492187
- ChEMBL
- CHEMBL4783351
- PDBe Ligand
- FJ0
- PDB Entries
- 7c2v
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Recruiting Treatment Anemia / Myelodysplastic Syndrome 1 1 Recruiting Treatment Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) / Stage III Pancreatic Cancer AJCC v8 / Stage IV Pancreatic Cancer AJCC v8 / Unresectable Pancreatic Ductal Adenocarcinoma 1 1, 2 Recruiting Treatment Acute Myeloid Leukemia / Myelodysplastic Syndrome 1 1, 2 Recruiting Treatment Refractory Hematologic Malignancy / Refractory Primary Central Nervous System Lymphoma / Relapsed Hematologic Malignancies / Relapsed Primary Central Nervous System Lymphoma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 1.32 Chemaxon pKa (Strongest Acidic) 12.92 Chemaxon pKa (Strongest Basic) 3.52 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 9 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 142.88 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 142.12 m3·mol-1 Chemaxon Polarizability 52.41 Å3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at September 08, 2023 20:29 / Updated at September 12, 2023 18:33